Sezen Karakus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sezen Karakus has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Esen Karamursel Akpek
The Ocular Surface Disease Clinic, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
8 shared publications Devika Agrawal
The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
4 shared publicationsEsen K. Akpek
The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA
3 shared publicationsPradeep Y. Ramulu
The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
3 shared publicationsUgur Tunc
Wilmer Eye Institute, Johns Hopkins University, 600 N. Wolfe Street, Baltimore, MD, USA
3 shared publicationsXi Zhu
Wilmer Eye Institute, Johns Hopkins University
3 shared publications
Latest Publications
- 24 October 2025
- Published by Elsevier in The Ocular Surface
- Vol. 38, 359-364
Eye pain and ocular surface characteristics in Postural Orthostatic Tachycardia Syndrome (POTS): The role of autonomic dysfunction
- 24 October 2025
- Published by Elsevier in The Ocular Surface
- Vol. 38, 359-364
Eye pain and ocular surface characteristics in Postural Orthostatic Tachycardia Syndrome (POTS): The role of autonomic dysfunction
- 1 October 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (10) , 2602-2604
Elevated Anti-Cyclic Citrullinated Peptide Levels Associated with Filamentary Keratitis
Purpose: To assess two cases of filamentary keratitis with elevated serum levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies without known rheumatoid arthritis (RA). Methods: A retrospective chart review was conducted on cases with filamentary keratitis and elevated anti-CCP antibodies between January 2021 and January 2023. Patient demographics, clinical characteristics, and serological test results were reviewed. Results: The first patient, a 77-year-old man, presented with foreign body sensation and eye redness. He reported mild dry mouth but no joint pain or known autoimmune disease, though he had a family history of RA. Schirmer test scores were 7 and 12 mm in the right and left eyes, with an ocular staining score (OSS) of 12 in each eye. His serum anti-CCP antibody level was >2,777 U. Over 3 years of follow-up, he showed no signs of RA development. The second patient, an 84-year-old man, presented with severe burning and light sensitivity but no dry mouth or joint pain. Schirmer test scores were 2 and 3 mm in the right and left eyes, with OSS of 9 and 5, respectively. His serum anti-CCP level was 1330 U. He developed inflammatory arthritis and was diagnosed with RA 16 months after initial presentation. Conclusion: This report suggests that filamentary keratitis with elevated serum anti-CCP antibody levels may indicate early RA. These findings underscore the importance of anti-CCP testing in filamentary keratitis patients, even without typical RA symptoms. Further research is needed to explore the link between anti-CCP antibodies and ocular surface diseases in RA.
- 1 October 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (10) , 2602-2604
Elevated Anti-Cyclic Citrullinated Peptide Levels Associated with Filamentary Keratitis
Purpose: To assess two cases of filamentary keratitis with elevated serum levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies without known rheumatoid arthritis (RA). Methods: A retrospective chart review was conducted on cases with filamentary keratitis and elevated anti-CCP antibodies between January 2021 and January 2023. Patient demographics, clinical characteristics, and serological test results were reviewed. Results: The first patient, a 77-year-old man, presented with foreign body sensation and eye redness. He reported mild dry mouth but no joint pain or known autoimmune disease, though he had a family history of RA. Schirmer test scores were 7 and 12 mm in the right and left eyes, with an ocular staining score (OSS) of 12 in each eye. His serum anti-CCP antibody level was >2,777 U. Over 3 years of follow-up, he showed no signs of RA development. The second patient, an 84-year-old man, presented with severe burning and light sensitivity but no dry mouth or joint pain. Schirmer test scores were 2 and 3 mm in the right and left eyes, with OSS of 9 and 5, respectively. His serum anti-CCP level was 1330 U. He developed inflammatory arthritis and was diagnosed with RA 16 months after initial presentation. Conclusion: This report suggests that filamentary keratitis with elevated serum anti-CCP antibody levels may indicate early RA. These findings underscore the importance of anti-CCP testing in filamentary keratitis patients, even without typical RA symptoms. Further research is needed to explore the link between anti-CCP antibodies and ocular surface diseases in RA.
- 29 June 2024
- Published by Elsevier in The Ocular Surface
- Vol. 34, 122-123
Scrambler therapy as a novel treatment for unilateral ocular neuropathic pain
- 29 June 2024
- Published by Elsevier in The Ocular Surface
- Vol. 34, 122-123
Scrambler therapy as a novel treatment for unilateral ocular neuropathic pain
- 15 March 2024
- Published by Elsevier in Ophthalmology
- Vol. 131 (9) , 1033-1044
Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye
- 15 March 2024
- Published by Elsevier in Ophthalmology
- Vol. 131 (9) , 1033-1044
Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye
- 6 February 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 250, 12-19
Cost and Prescriber and Patient Characteristics of Cenegermin Use in the Medicare Population
- 6 February 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 250, 12-19
Cost and Prescriber and Patient Characteristics of Cenegermin Use in the Medicare Population
- Open Access
- 28 July 2022
- Published by Springer Nature in Research Square
Topical Recombinant Human Nerve Growth Factor for Management of Refractory Epithelial Keratopathy
Severe epithelial keratopathy refractory to conventional dry eye treatment in the absence of discomfort symptoms should raise suspicion for neurotrophic corneal changes. This study aimed to evaluate the effect of topical recombinant human nerve growth factor (rhNGF) eye drops in managing refractory epithelial keratopathy with neurotrophic features. This was a retrospective case series study on patients treated with topical rhNGF for refractory epithelial keratopathy due to stage I neurotrophic keratitis (NK) at a single institution. Data regarding demographics and ocular/systemic medical history was extracted from patient charts. Visual acuity and corneal staining scores were recorded at baseline and follow-up visits, along with treatment side effects. We included 26 eyes of 14 patients with refractory epithelial keratopathy. After an 8-week treatment course, the median corneal staining score in the worse eye decreased from 4 to 1 (p=0.001). All patients showed at least one-grade improvement in corneal staining with complete or near-complete resolution in at least one eye at 8 weeks, sustained in 7 patients at three months. A better response was observed in eyes with post-radiation epithelial keratopathy, LASIK, and Sjogren's syndrome. Those with chronic use of other topical treatments and uncontrolled diabetes mellitus demonstrated incomplete responses. Eight patients reported mild to moderate ocular discomfort from drop application that fully resolved after completion of treatment. Topical rhNGF application was effective and safe in treating refractory epithelial keratopathy due to stage I NK in our cohort, although the effect was sustained only in some patients at three months. Further studies are needed to determine the optimum treatment regimen based on underlying etiology.
- 28 July 2022
- Published by Springer Nature in Research Square
Open AccessTopical Recombinant Human Nerve Growth Factor for Management of Refractory Epithelial Keratopathy
Severe epithelial keratopathy refractory to conventional dry eye treatment in the absence of discomfort symptoms should raise suspicion for neurotrophic corneal changes. This study aimed to evaluate the effect of topical recombinant human nerve growth factor (rhNGF) eye drops in managing refractory epithelial keratopathy with neurotrophic features. This was a retrospective case series study on patients treated with topical rhNGF for refractory epithelial keratopathy due to stage I neurotrophic keratitis (NK) at a single institution. Data regarding demographics and ocular/systemic medical history was extracted from patient charts. Visual acuity and corneal staining scores were recorded at baseline and follow-up visits, along with treatment side effects. We included 26 eyes of 14 patients with refractory epithelial keratopathy. After an 8-week treatment course, the median corneal staining score in the worse eye decreased from 4 to 1 (p=0.001). All patients showed at least one-grade improvement in corneal staining with complete or near-complete resolution in at least one eye at 8 weeks, sustained in 7 patients at three months. A better response was observed in eyes with post-radiation epithelial keratopathy, LASIK, and Sjogren's syndrome. Those with chronic use of other topical treatments and uncontrolled diabetes mellitus demonstrated incomplete responses. Eight patients reported mild to moderate ocular discomfort from drop application that fully resolved after completion of treatment. Topical rhNGF application was effective and safe in treating refractory epithelial keratopathy due to stage I NK in our cohort, although the effect was sustained only in some patients at three months. Further studies are needed to determine the optimum treatment regimen based on underlying etiology.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 127-133
Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients Presenting with Conjunctivitis During the COVID-19 Pandemic
Purpose: To investigate the prevalence of SARS-CoV-2-associated conjunctivitis among patients presenting with conjunctivitis to ophthalmology clinics in the absence of respiratory symptoms suggesting COVID-19 during the first year of the pandemic. Patients and Methods: This prospective, observational, cross-sectional study enrolled patients aged 18 years and older who presented with acute conjunctivitis between May 2020 and May 2021. After reviewing demographics, ocular and systemic symptoms, a slit lamp examination was performed. Five samples were collected (conjunctival swab from each eye, nasal swab from each nostril, and a nasopharyngeal swab) in separate tubes for a reverse transcription-polymerase chain reaction test for SARS-CoV-2. Patients were called at 1 and 2 weeks to follow up on their ocular and systemic symptoms and collect information about conjunctival adenovirus test results and COVID-19 test results if performed outside of the study. Results: A total of 36 patients were enrolled. The most common ocular symptom was redness (35/36, 97%), and 14 patients (39%) had symptoms in both eyes at the time of the presentation. SARS-CoV-2 RNA was not detected in any samples collected during the study visit (95% confidence interval [CI] from 0 to 0.08). None of the study participants were diagnosed with COVID-19 following conjunctivitis during the 2-week follow-up period. We found that 25 patients had a conjunctival adenovirus test done on the day of their study visit, 9 of which reported positive results. Conclusion: Our data suggest that it may not be valuable to obtain routine testing of SARS-CoV-2 in patients presenting with conjunctivitis in the absence of COVID-19.
- 1 January 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 127-133
Open AccessPrevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients Presenting with Conjunctivitis During the COVID-19 Pandemic
Purpose: To investigate the prevalence of SARS-CoV-2-associated conjunctivitis among patients presenting with conjunctivitis to ophthalmology clinics in the absence of respiratory symptoms suggesting COVID-19 during the first year of the pandemic. Patients and Methods: This prospective, observational, cross-sectional study enrolled patients aged 18 years and older who presented with acute conjunctivitis between May 2020 and May 2021. After reviewing demographics, ocular and systemic symptoms, a slit lamp examination was performed. Five samples were collected (conjunctival swab from each eye, nasal swab from each nostril, and a nasopharyngeal swab) in separate tubes for a reverse transcription-polymerase chain reaction test for SARS-CoV-2. Patients were called at 1 and 2 weeks to follow up on their ocular and systemic symptoms and collect information about conjunctival adenovirus test results and COVID-19 test results if performed outside of the study. Results: A total of 36 patients were enrolled. The most common ocular symptom was redness (35/36, 97%), and 14 patients (39%) had symptoms in both eyes at the time of the presentation. SARS-CoV-2 RNA was not detected in any samples collected during the study visit (95% confidence interval [CI] from 0 to 0.08). None of the study participants were diagnosed with COVID-19 following conjunctivitis during the 2-week follow-up period. We found that 25 patients had a conjunctival adenovirus test done on the day of their study visit, 9 of which reported positive results. Conclusion: Our data suggest that it may not be valuable to obtain routine testing of SARS-CoV-2 in patients presenting with conjunctivitis in the absence of COVID-19.
- 2 January 2021
- Published by Taylor & Francis in Expert Review of Ophthalmology
- Vol. 16 (1) , 11-18
The role of lid margin structures in the meibomian gland function and ocular surface health
Introduction: The lid margins are essential to maintain a healthy tear film and distribute it over the ocular surface to achieve an optimal refractive interface. Alterations in the lid margin structures and function may lead to significant ocular surface problems. Meibomian gland dysfunction is usually attributed to be the most common reason for ocular surface disease. However, the lid margin disease cannot be fully understood and adequately addressed if the function of the meibomian glands is not evaluated in relation to other lid margin structures. Areas covered: This review aims to emphasize that the lid margin requires a full assessment in order to address ocular surface diseases associated with lid margin disease. The different zones of the lid margin and their roles in the maintenance of ocular surface health are delineated. Alterations in the lid margin structures due to increasing age or underlying etiology and their potential impact are discussed. Expert commentary: If structural abnormalities are not recognized and properly addressed, the treatment of meibomian gland dysfunction will likely fail. Future studies focusing on the underlying etiology of structural alterations will hopefully lead to the development of more effective therapeutic options.
- 2 January 2021
- Published by Taylor & Francis in Expert Review of Ophthalmology
- Vol. 16 (1) , 11-18
The role of lid margin structures in the meibomian gland function and ocular surface health
Introduction: The lid margins are essential to maintain a healthy tear film and distribute it over the ocular surface to achieve an optimal refractive interface. Alterations in the lid margin structures and function may lead to significant ocular surface problems. Meibomian gland dysfunction is usually attributed to be the most common reason for ocular surface disease. However, the lid margin disease cannot be fully understood and adequately addressed if the function of the meibomian glands is not evaluated in relation to other lid margin structures. Areas covered: This review aims to emphasize that the lid margin requires a full assessment in order to address ocular surface diseases associated with lid margin disease. The different zones of the lid margin and their roles in the maintenance of ocular surface health are delineated. Alterations in the lid margin structures due to increasing age or underlying etiology and their potential impact are discussed. Expert commentary: If structural abnormalities are not recognized and properly addressed, the treatment of meibomian gland dysfunction will likely fail. Future studies focusing on the underlying etiology of structural alterations will hopefully lead to the development of more effective therapeutic options.
- 5 April 2020
- Published by Wolters Kluwer Health in Cornea
- Vol. 39 (8) , 991-997
Differential Diagnosis of Sjögren Versus Non-Sjögren Dry Eye Through Tear Film Biomarkers
Purpose: Systemic implications necessitate the identification of dry eye patients with Sjögren syndrome (SS). This study aims to explore the utility of tear MUC5AC and inflammatory cytokine levels in the differential diagnosis of SS-related dry eye. Methods: A prospective, observational, case-control study was conducted on 62 patients (those with a definitive diagnosis of SS dry eye, non-SS dry eye, and age-matched healthy controls with no dry eye). Clinical evaluations included the following tests in the order listed here: noninvasive tear break-up time, osmolarity, tear sampling, Schirmer test without anesthesia, and ocular surface staining (lissamine green for conjunctiva and fluorescein for cornea). Tear MUC5AC levels were assessed with enzyme-linked immunosorbent assay, and cytokines [interferon-gamma, tumor necrosis factor alpha, interleukin (IL)-6, IL-17a, IL-1β, IL-8, IL-10, and IL-12p70] were measured using a Luminex assay in a masked fashion. Results: The Bulbar conjunctival lissamine green staining score was significantly greater in patients or controls with SS versus non-SS dry eye. This greater conjunctival staining was associated with a reduction in tear MUC5AC (B = −17.8 ng/mL, 95% confidence interval = −31.8 to −3.9, P = 0.01). Among the tear cytokines, a significant association was found between IL-8 levels (hazard ratio [HR] = 1.002, 95% confidence interval = 1.000–1.003, P = 0.03) and SS diagnosis. When patients were stratified based on tear MUC5AC levels, significantly increased tear IL-8 levels were detected in patients with SS dry eye but not with non-SS dry eye, in comparison with healthy controls. Conclusions: Tear levels of goblet cell-specific MUC5AC combined with IL-8 can potentially serve as a useful biomarker for differential diagnosis of SS dry eye from non-SS dry eye.
- 5 April 2020
- Published by Wolters Kluwer Health in Cornea
- Vol. 39 (8) , 991-997
Differential Diagnosis of Sjögren Versus Non-Sjögren Dry Eye Through Tear Film Biomarkers
Purpose: Systemic implications necessitate the identification of dry eye patients with Sjögren syndrome (SS). This study aims to explore the utility of tear MUC5AC and inflammatory cytokine levels in the differential diagnosis of SS-related dry eye. Methods: A prospective, observational, case-control study was conducted on 62 patients (those with a definitive diagnosis of SS dry eye, non-SS dry eye, and age-matched healthy controls with no dry eye). Clinical evaluations included the following tests in the order listed here: noninvasive tear break-up time, osmolarity, tear sampling, Schirmer test without anesthesia, and ocular surface staining (lissamine green for conjunctiva and fluorescein for cornea). Tear MUC5AC levels were assessed with enzyme-linked immunosorbent assay, and cytokines [interferon-gamma, tumor necrosis factor alpha, interleukin (IL)-6, IL-17a, IL-1β, IL-8, IL-10, and IL-12p70] were measured using a Luminex assay in a masked fashion. Results: The Bulbar conjunctival lissamine green staining score was significantly greater in patients or controls with SS versus non-SS dry eye. This greater conjunctival staining was associated with a reduction in tear MUC5AC (B = −17.8 ng/mL, 95% confidence interval = −31.8 to −3.9, P = 0.01). Among the tear cytokines, a significant association was found between IL-8 levels (hazard ratio [HR] = 1.002, 95% confidence interval = 1.000–1.003, P = 0.03) and SS diagnosis. When patients were stratified based on tear MUC5AC levels, significantly increased tear IL-8 levels were detected in patients with SS dry eye but not with non-SS dry eye, in comparison with healthy controls. Conclusions: Tear levels of goblet cell-specific MUC5AC combined with IL-8 can potentially serve as a useful biomarker for differential diagnosis of SS dry eye from non-SS dry eye.
- 1 January 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 209, 3-9
Characterization of Progressive Cicatrizing Conjunctivitis With Negative Immunofluorescence Staining
- 1 January 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 209, 3-9
Characterization of Progressive Cicatrizing Conjunctivitis With Negative Immunofluorescence Staining